Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC
A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.
Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer
Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.
Acalabrutinib Combo Appears Tolerable, Effective in R/R B-Cell Lymphoma
More than half of the patients with relapsed/refractory B-cell lymphoma achieve a complete response with acalabrutinib plus axicabtagene ciloleucel in a phase 1/2 trial.
Olaparib Combo Improves Survival Vs Placebo in Metastatic CRPC
Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.
Zanubrutinib/Ibrutinib in CLL Yields Low BTK/PLCG2 Mutation Incidence
Patients with chronic lymphocytic leukemia in the ALPINE study previously treated with BTK inhibitors are likely to remain sensitive to other BTK-targeting agents, says Jennifer Brown, MD, PhD.
Pirtobrutinib Effective in Heavily Pretreated BTK–Mutated CLL
Pirtobrutinib produces a high rate of responses in patients with relapsed chronic lymphocytic leukemia harboring baseline BTK mutations, according to findings from the phase 1/2 BRUIN trial.
Novel BTK Degrader Yields Responses in R/R B-Cell Malignancies
Data from a phase 1 study support further analysis of BGB-16673 across several B-cell malignancies, according to the study investigators.
Axi-cel Plus Bridging Therapy Yield Similar Real-world Data in R/R LBCL
A 70% overall response rate was observed when bridging therapy was added to axi-cel for patients with relapsed/refractory large B-cell lymphoma.
Data Highlight Similar RFS in White and Black Breast Cancer Populations
Data highlight the importance of genomic testing to help optimize treatment and reduce disparities for Black patients with hormone receptor–positive HER2-negative breast cancer, according to Sonya Reid, MD, MPH.
Dabrafenib Combo Shows Complete Responses in BRAF V600+ Metastatic Melanoma
Targeting apoptosis in BRAF V600-mutated melanoma may be considered for future exploration in the post immunotherapy setting, according to an expert at Moffitt Cancer Center.
Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population
Nirogacestat also appears to improve progression-free survival compared with placebo among those with desmoid tumors in the phase 3 DeFi trial.